Overview

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborators:
Bayer
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride
Gemcitabine
Niacinamide
Sorafenib